Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2001 Dec;1(3):233-40.

Assessing TP53 status in human tumours to evaluate clinical outcome.

Author information

1
Institut Curie, Université P. & M. Curie, Laboratoire de Génotoxicologie des Tumeurs, Paris, France. thierry.soussi@curie.fr

Abstract

TP53 is probably the most extensively studied tumour-suppressor gene, and patients with TP53 mutations are known to have a poor outcome. However, inconsistencies in the analysis of TP53 status, and failure to realize that different mutations behave in different ways, prevent us from effectively applying our vast knowledge of this protein in clinical practice. What simple steps can be taken to ensure that patients benefit from our understanding of TP53?

PMID:
11902578
DOI:
10.1038/35106009
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center